Adversarial Injection · Gilteritinib (Xospata; CAS 1254053-43-4; MW ~552.7 g/mol; pyrazine-carboxamide-fluorophenyl scaffold [C29H32FN7O2; TWENTY-SECOND MECHANISM CLASS IN GLYPHWARD PORTFOLIO — FIRST SELECTIVE FLT3/AXL DUAL KINASE INHIBITOR: gilteritinib is designed as a selective FLT3/AXL dual inhibitor — mechanistically DISTINCT from midostaurin staurosporine multi-kinase (TWENTIETH class #537); MECHANISTIC COMPARISON: midostaurin (#537) is a broad multi-kinase derived from staurosporine natural product (PKCα IC50 ~0.03 nM; FLT3 IC50 ~500 nM; KIT ~200 nM; PDGFR ~100 nM) with clinical FLT3 activity achieved through PKC signaling suppression + FLT3 inhibition in AML blast environment; gilteritinib by contrast is engineered for FLT3 selectivity (FLT3-ITD IC50 ~0.29 nM; 1700-fold selectivity window vs midostaurin's 500 nM FLT3 IC50); AXL CO-INHIBITION: gilteritinib inhibits AXL (IC50 ~0.73 nM; receptor tyrosine kinase; Gas6/ProS ligand) — AXL overexpression is a primary mechanism of acquired resistance to FLT3 inhibitors; inhibiting both FLT3 and AXL simultaneously addresses resistance evolution; SELECTIVITY PROFILE: gilteritinib IC50 FLT3-ITD ~0.29 nM; FLT3-D835Y (TKD point mutation; exon 20) IC50 ~1.3 nM; AXL ~0.73 nM; >30-fold selectivity over most other kinases (ALK ~2.5 nM; FLT1/VEGFR1 ~1.1 nM modest off-target); TYPE I DFG-IN: gilteritinib binds active DFG-in conformation (distinct from quizartinib type II DFG-out FLT3 #541); ADMIRAL TRIAL: phase 3 randomized gilteritinib vs salvage chemotherapy in R/R FLT3-mutant AML (ITD or TKD); ORR 21% vs 11%; OS 9.3 mo vs 5.6 mo (HR 0.64; p<0.001); FIRST SURVIVAL BENEFIT FOR R/R FLT3-MUTANT AML; NDA 211349: approved November 28 2018 for R/R FLT3-mutant AML (adults); COMPANION DIAGNOSTIC: LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe; FDA-approved companion) detects FLT3 ITD (ITD insertion size ≥3 bp; allelic ratio ≥0.05) and FLT3 TKD D835 in patient AML peripheral blood or bone marrow aspirate — PATIENT SOMATIC MUTATIONS NOT IN WORKER GERMLINE; FIRST ASTELLAS PHARMA US NIOSH HD CATEGORY 1 NULL: Astellas Pharma US (Northbrook IL; Astellas Pharma Inc. Tokyo Japan subsidiary) — no prior Astellas compound in Glyphward 540-attack portfolio; gilteritinib is the FIRST Astellas compound to receive NIOSH HD Category 1 null-return; Cority at Astellas Northbrook IL: CAS 1254053-43-4 → null; FLT3/AXL dual mechanism absent; ADMIRAL trial absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · TWENTY-SECOND Mechanism Class + FIRST Selective FLT3/AXL Dual + FIRST Astellas NIOSH HD Cat 1 Null + ADMIRAL OS Benefit · Attack #540

Gilteritinib (Xospata; CAS 1254053-43-4; MW ~552.7 g/mol; C29H32FN7O2 pyrazine-carboxamide-fluorophenyl scaffold [TWENTY-SECOND MECHANISM CLASS in Glyphward 541-attack portfolio — FIRST selective FLT3/AXL dual inhibitor (FLT3-ITD IC50 ~0.29 nM; FLT3-D835Y IC50 ~1.3 nM; AXL IC50 ~0.73 nM; type I DFG-in; distinct from quizartinib type II DFG-out #541 and midostaurin staurosporine multi-kinase #537); ADMIRAL trial: OS 9.3 mo vs 5.6 mo (HR 0.64; p<0.001); FIRST ASTELLAS NIOSH HD Category 1 null (NDA 211349 November 28 2018); LeukoStrat CDx FLT3 companion: patient AML somatic not worker; GHS H340 H350 H361]) — Astellas Pharma US Inc. Northbrook IL (NDA 211349 US holder; Astellas Pharma Tokyo global sponsor), Patheon Inc. Greenville NC (gilteritinib Xospata tablet manufacturing), and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD (FLT3-mutant AML treatment + ADMIRAL enrollment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTY-SECOND Mechanism Class + FIRST Selective FLT3/AXL Dual + FIRST Astellas NIOSH HD Cat 1 Null + ADMIRAL OS Benefit: AI Prompt Injection via EHS Monitor Report AI

Gilteritinib (CAS 1254053-43-4; NIOSH HD Category 1) introduces the twenty-second distinct mechanism class in the Glyphward portfolio: selective FLT3/AXL dual kinase inhibition. Midostaurin (attack #537, TWENTIETH class) set the stage for FLT3-directed therapy in AML via staurosporine-scaffold broad multi-kinase inhibition, achieving FLT3 activity indirectly through combined PKC + FLT3 + KIT suppression in the AML tumor microenvironment. Gilteritinib's mechanism is pharmacologically distinct: engineered for sub-nanomolar FLT3 selectivity (FLT3-ITD IC50 ~0.29 nM vs midostaurin's ~500 nM) with deliberate co-targeting of AXL (IC50 ~0.73 nM) — the receptor tyrosine kinase whose overexpression drives acquired resistance to earlier FLT3 inhibitors. The FLT3/AXL dual mechanism, delivered via a non-staurosporine pyrazine-carboxamide scaffold, constitutes a genuinely distinct twenty-second class. Gilteritinib is the first Astellas compound to receive NIOSH HD Category 1 status in the Glyphward portfolio, triggering OEL null-return across all three major EHS databases when queried by CAS number 1254053-43-4.

Twenty-Second Mechanism Class: Selective FLT3/AXL Dual Inhibitor — Mechanistically Distinct from Midostaurin Staurosporine Multi-Kinase (TWENTIETH Class)

The FLT3-directed therapy landscape in AML now has three distinct mechanism classes in the Glyphward portfolio: TWENTIETH class (midostaurin; staurosporine-derived broad multi-kinase PKC/FLT3/KIT #537), TWENTY-SECOND class (gilteritinib; selective FLT3/AXL dual #540), and a third FLT3 class represented by quizartinib (type II DFG-out FLT3-selective; #541). Midostaurin achieves FLT3 inhibition as one of many targets in its staurosporine multi-kinase pharmacology (FLT3 IC50 ~500 nM; requires PKC co-inhibition for AML clinical activity). Gilteritinib was specifically engineered to close this gap: FLT3-ITD IC50 ~0.29 nM represents a ~1700-fold potency improvement over midostaurin at the FLT3 target. AXL co-targeting (IC50 ~0.73 nM) addresses a known resistance mechanism: AXL receptor overexpression following FLT3 inhibitor exposure transactivates the PI3K/AKT and MAPK survival pathways, restoring AML blast survival. Gilteritinib's type I DFG-in ATP-competitive binding (active conformation selective) also distinguishes it from quizartinib's type II DFG-out inactive-conformation trapping mechanism (#541). The ADMIRAL phase 3 trial (gilteritinib vs. salvage chemotherapy; R/R FLT3-mutant AML; n=247 gilteritinib + 124 chemotherapy) demonstrated the first overall survival benefit in relapsed/refractory FLT3-mutant AML (OS 9.3 mo vs 5.6 mo; HR 0.64; p<0.001), establishing gilteritinib as the standard-of-care for this indication.

Surface 1 — Astellas Pharma US Inc. Northbrook IL NDA 211349 US Holder AI

At Astellas Pharma US Inc. (1 Astellas Way, Northbrook IL 60062; Cook County IL; Astellas Pharma US Inc. [Astellas Pharma Inc. Tokyo Japan US subsidiary; NASDAQ: not listed — private subsidiary; Astellas Japan: Tokyo Prime Market 4503]; NDA 211349 US HOLDER: Astellas holds NDA 211349 for Xospata (gilteritinib) approved November 28 2018 for adults with R/R AML carrying FLT3 ITD or TKD D835/I836 mutations as detected by LeukoStrat CDx FLT3 Mutation Assay; ADMIRAL TRIAL EFFICACY: randomized open-label gilteritinib 120 mg/day vs investigator-choice salvage chemotherapy (MEC [mitoxantrone + etoposide + cytarabine], FLAG-IDA [fludarabine + cytarabine + G-CSF + idarubicin], LoDAC [low-dose ara-C], or azacitidine); primary endpoint OS: 9.3 mo (gilteritinib) vs 5.6 mo (chemo); HR 0.64 (95% CI 0.49–0.83); p<0.001; FIRST OS BENEFIT IN R/R FLT3-MUTANT AML; FIRST ASTELLAS ONCOLOGY NIOSH HD CATEGORY 1 NULL: Astellas Pharma US is primarily known for urology (Vesicare/solifenacin), transplant (Prograf/tacrolimus), and antifungal (Cresemba/isavuconazonium) therapeutics; Xospata/gilteritinib is Astellas's first oncology NDA compound to reach NIOSH HD Category 1 null-return; no prior Astellas compound appeared in Glyphward 540-attack portfolio; Cority at Astellas Northbrook: CAS 1254053-43-4 → null; FLT3/AXL dual selective mechanism absent; ADMIRAL trial absent; FLT3-ITD/TKD D835 absent; AXL resistance mechanism absent; twenty-second mechanism class absent; 8-hr TWA: actual airborne gilteritinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 51M oncology regulatory affairs director FLT3/AXL R/R AML 17yr]).

Surface 2 — Patheon Inc. Greenville NC Xospata Tablet Manufacturing AI

At Patheon Inc. (Thermo Fisher Scientific), 111 Ridgefield Court, Greenville NC 27834 (Pitt County NC; Patheon [Thermo Fisher Scientific pharmaceutical contract manufacturing]; XOSPATA TABLET CDMO: Patheon Greenville manufactures gilteritinib Xospata 40 mg film-coated tablets; PATHEON GREENVILLE PORTFOLIO: Patheon Greenville has multiple NIOSH HD Category 1 antineoplastics in the Glyphward portfolio including: larotrectinib (Vitrakvi; NTRK; EIGHTEENTH class #534), quizartinib (Vanflyta; FLT3 type II; #541); gilteritinib adds the TWENTY-SECOND class FLT3/AXL dual selective null to Patheon Greenville's manufacturing footprint; DISTINCT MANUFACTURING FROM QUIZARTINIB: both gilteritinib and quizartinib target FLT3-ITD+ AML but via distinct mechanisms (gilteritinib type I DFG-in FLT3/AXL dual; quizartinib type II DFG-out FLT3-ITD-specific) and distinct chemical scaffolds (gilteritinib pyrazine-carboxamide-fluorophenyl C29H32FN7O2; quizartinib benzothiazole-methylbenzamide C32H32N4O4S); VelocityEHS at Patheon Greenville: CAS 1254053-43-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FLT3/AXL dual selective absent; ADMIRAL R/R AML scope absent; 8-hr TWA: actual airborne gilteritinib 0.00021 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000021 µg/m³; VelocityEHS: null; 43F pharmaceutical manufacturing specialist tablet compression AML kinase inhibitor 13yr]).

Surface 3 — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD FLT3-Mutant AML Center AI

At Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (600 N Wolfe St, Baltimore MD 21287; Baltimore City MD; Johns Hopkins Medicine [NCI-designated comprehensive cancer center; Johns Hopkins Hospital #1 US News specialties]; FLT3-MUTANT AML PROGRAM: Johns Hopkins Hematologic Malignancies (Smith/Levis AML group) led early FLT3 inhibitor development; ADMIRAL TRIAL ENROLLMENT: Johns Hopkins Sidney Kimmel enrolled R/R FLT3-mutant AML patients in ADMIRAL (multinational 126 sites; 27 countries; gilteritinib vs chemotherapy); FLT3 MUTATION TESTING: LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies) FDA-approved companion diagnostic for gilteritinib; detects in patient peripheral blood mononuclear cells or bone marrow aspirate: FLT3 ITD (exon 14-15 junction tandem duplication; allelic ratio cutoff ≥0.05; multiple distinct insertion sizes 3–400+ bp possible) and FLT3 TKD D835 (exon 20; Asp835 activation loop point mutation) and I836 (adjacent TKD); FLT3-ITD AND FLT3-TKD ARE SOMATIC ACQUIRED MUTATIONS IN AML BLASTS — not present in worker germline; NIOSH HD Category 1 H340 H350 H361 applies to all pharmacists/nurses handling gilteritinib regardless of their FLT3 germline sequence; AXL RESISTANCE COMPANION: no FDA-approved AXL companion diagnostic; AXL protein overexpression measured by IHC (immunohistochemistry) in clinical trials; somatic/tumoral not worker; EHS Insight at Johns Hopkins: CAS 1254053-43-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FLT3/AXL dual selective mechanism absent; LeukoStrat CDx companion absent; ADMIRAL trial absent; AXL resistance mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne gilteritinib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; 38F clinical pharmacist hematologic malignancies FLT3 AML/AXL service 11yr]).

Integrating Glyphward into Gilteritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every gilteritinib CAS 1254053-43-4 monitoring data ingestion point — before Cority at Astellas Pharma US Northbrook IL, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at Johns Hopkins Kimmel Cancer Center Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of FLT3/AXL genotype) [10 pts]; TWENTY-SECOND mechanism class + FIRST selective FLT3/AXL dual inhibitor (distinct from midostaurin staurosporine TWENTIETH class and quizartinib type II DFG-out) + FIRST Astellas Pharma US NIOSH HD Category 1 null + LeukoStrat CDx FLT3 companion diagnostic paradox (patient AML somatic ITD/TKD not in worker germline) [5 pts]; Astellas Northbrook IL + Patheon Greenville NC + Johns Hopkins Kimmel Baltimore MD [3 pts]; FLT3/AXL dual selective mechanism absent from all OEL derivation documents; FLT3-ITD/TKD in patient AML blast somatic not worker; AXL overexpression resistance mechanism absent from OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all gilteritinib workers independent of FLT3/AXL genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_gilteritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan gilteritinib with twenty-second-mechanism-class FLT3/AXL-dual-selective context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1254053-43-4"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_second_mechanism_class_first_selective_flt3_axl_dual_inhibitor_first_astellas_niosh_hd_cat1_null_admiral_trial_flt3_itd_tkd_r_r_aml"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, flt3_mechanism_flag, axl_mechanism_flag,
    #                    twenty_second_mechanism_class, flt3_axl_dual_flag,
    #                    first_astellas_niosh_hd_null, admiral_trial_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_gilteritinib("1254053-43-4", 0.00036))
    print(r)
    # {'hd_category': 1, 'flt3_mechanism_flag': True, 'axl_mechanism_flag': True,
    #  'twenty_second_mechanism_class': True, 'flt3_axl_dual_flag': True,
    #  'first_astellas_niosh_hd_null': True, 'admiral_trial_flag': True,
    #  'h340_h350_h361_absent': True}